GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » DermTech Inc (NAS:DMTK) » Definitions » EV-to-EBIT
中文

DermTech (DermTech) EV-to-EBIT : -0.19 (As of Apr. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is DermTech EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, DermTech's Enterprise Value is $19.86 Mil. DermTech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-103.74 Mil. Therefore, DermTech's EV-to-EBIT for today is -0.19.

The historical rank and industry rank for DermTech's EV-to-EBIT or its related term are showing as below:

DMTK' s EV-to-EBIT Range Over the Past 10 Years
Min: -42.75   Med: -2.75   Max: 0.65
Current: -0.19

During the past 8 years, the highest EV-to-EBIT of DermTech was 0.65. The lowest was -42.75. And the median was -2.75.

DMTK's EV-to-EBIT is ranked worse than
100% of 108 companies
in the Medical Diagnostics & Research industry
Industry Median: 20.19 vs DMTK: -0.19

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. DermTech's Enterprise Value for the quarter that ended in Dec. 2023 was $58.95 Mil. DermTech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-103.74 Mil. DermTech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -175.98%.


DermTech EV-to-EBIT Historical Data

The historical data trend for DermTech's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DermTech EV-to-EBIT Chart

DermTech Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial -27.86 -17.27 -3.27 0.14 -0.57

DermTech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 -0.54 -0.46 -0.32 -0.57

Competitive Comparison of DermTech's EV-to-EBIT

For the Diagnostics & Research subindustry, DermTech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DermTech's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, DermTech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where DermTech's EV-to-EBIT falls into.



DermTech EV-to-EBIT Calculation

DermTech's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=19.858/-103.739
=-0.19

DermTech's current Enterprise Value is $19.86 Mil.
DermTech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-103.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DermTech  (NAS:DMTK) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

DermTech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-103.739/58.948225
=-175.98 %

DermTech's Enterprise Value for the quarter that ended in Dec. 2023 was $58.95 Mil.
DermTech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-103.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DermTech EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of DermTech's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


DermTech (DermTech) Business Description

Traded in Other Exchanges
N/A
Address
11099 N. Torrey Pines Road, Suite 100, La Jolla, CA, USA, 92037
DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.
Executives
Kevin M Sun officer: Chief Financial Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Claudia Ibarra officer: Chief Operating Officer C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Ramin Akhavan officer: General Counsel C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Mark Bryan Aguillard officer: Chief Commercial Officer 19800 CORDILL LANE, SPICEWOOD TX 78669
Todd Michael Wood officer: Chief Commercial Officer C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Bret Christensen director, officer: Chief Executive Officer 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
John Dobak director, officer: Chief Executive Officer 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Kirk Malloy director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Mark Christopher Capone director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Herm Rosenman director OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
Nathalie Gerschtein Keraudy director C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Monica Tellado director C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Enrico Picozza director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew L. Posard director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037

DermTech (DermTech) Headlines

From GuruFocus